This hypothesis warrants further investigation, since determining the factors and pathways responsible for this enabling crosstalk could help design targeted therapies that inhibit the tumor-initiating effects of cells that have lost ANCO1 expression. The gene discussed is ANKRD11; the disease is neoplasm.